Moderna Receives U.S. FDA Approval for Updated COVID-19 …
WEBAug 22, 2024 · SPIKEVAX (COVID-19 Vaccine, mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older.
Moderna - Wikipedia
WEBThe company's commercial products are the Moderna COVID-19 vaccine, marketed as Spikevax and a RSV vaccine, marketed as Mresvia. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials .
FDA Approves and Authorizes Updated mRNA COVID-19 Vaccines …
WEBAug 22, 2024 · Today, the U.S. Food and Drug Administration approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines (2024-2025 formula) to include a monovalent (single) component...
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine Spikevax
WEBJan 31, 2022 · The totality of real-world data and the full BLA for Spikevax in the United States reaffirms the importance of vaccination against this virus. This is a momentous milestone in Moderna's history as it is our first product to achieve licensure in the U.S.," said Stéphane Bancel, Chief Executive Officer of Moderna.
Moderna COVID-19 vaccine - Wikipedia
WEBThe Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
Moderna Announces Changes to Commercial Organization to …
WEBDec 12, 2023 · The Company has decided to increase executive focus on driving sales of Spikevax and the expected launch of its RSV vaccine next year. To do this, Stephane Bancel, Chief Executive Officer of Moderna, will assume responsibility for sales and marketing in 2024, working directly with the commercial team.
Celebrating U.S. FDA Approval of Our Updated COVID-19 Vaccine
WEBChief Executive Officer. Print page / Save as PDF. I am pleased to announce that the U.S. Food and Drug Administration (FDA) has approved our supplemental Biologics License Application (sBLA) for Spikevax® (COVID-19 Vaccine, mRNA) for individuals 12 years of age and older, which helps protect against the most dominant variants as recommended ...
Moderna Receives U.S. FDA Approval for Updated COVID-19
WEBAug 22, 2024 · Moderna, Inc. today announced the U.S. Food and Drug Administration has approved the supplemental Biologics License Application for Spikevax ® for individuals 12 years and above.
Spikevax (COVID-19 Vaccine, mRNA) 2024-2025 Formula - Moderna
WEBLearn about Moderna's Spikevax® (COVID-19 Vaccine, mRNA) 2024-2025 Formula and how it helps protect against emerging variants, following ACIP recommendation.
Our Story - Moderna
WEBModerna begins research into the production of mRNA medicines. Stéphane Bancel joins as founding CEO.